Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

SOCS2 polymorphisms are not associated with clinical and biochemical phenotypes in acromegalic patients.

Pituitary - 1 Jun 2017

Trarbach Ericka B, Jorge Alexander A, Duarte Felipe H, Bronstein Marcello D, Jallad Raquel S

Abstract excerpt

PURPOSE: Suppressor of cytokine signaling 2 (SOCS2) is a STAT5b-regulated gene and one of its functions is to influence growth and development through negative regulatory effects on GH/IGF-1 pathway. So, we evaluate the potential influence of SOCS2 single nucleotide polymorphisms (SNPs) on clinical and laboratorial characteristics of a large cohort of Brazilian patients with acromegaly. METHODS: Four SOCS2 SNPs...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acromegaly
Share to Body Mass Index
Share to Genotype

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Insulin-Like Growth Factor I

Share to Phenotype

Share to Polymorphism, Genetic

Share to Signal Transduction

Share to Suppressor of Cytokine Signaling Proteins

Source

Identifiers

PMID: 27900634
DOI: 10.1007/s11102-016-0779-1

Genes

SOCS2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

SOCS2 polymorphisms are not associated with clinical and biochemical phenotypes in acromegalic patients.PMID 27900634Read ↗

Genetic Predictors of Response to Different Medical Therapies in Acromegaly.Semantic proximity Read ↗

Influence of growth hormone receptor (GHR) exon 3 and -202A/C IGFBP-3 genetic polymorphisms on clinical and biochemical features and therapeutic outcome of patients with acromegaly.Semantic proximity Read ↗

Genetic predictors of long-term response to growth hormone (GH) therapy in children with GH deficiency and Turner syndrome: the influence of a SOCS2 polymorphism.Semantic proximity Read ↗

Analysis of somatostatin receptors 2 and 5 polymorphisms in patients with acromegaly.Semantic proximity Read ↗

Identification of somatostatin receptor type 5 gene polymorphisms associated with acromegaly.Semantic proximity Read ↗

Klotho gene G395A and C1818T polymorphisms in acromegaly: Association with clinical presentation and comorbidities.Semantic proximity Read ↗

The Potential Roles of 77C>T Variant and Growth Hormone-Releasing Hormone Elevation in Pituitary Adenoma Cases Associated with AcromegalySemantic proximity Read ↗

gsp Mutation Is Not a Molecular Biomarker of Long-Term Response to First-Generation Somatostatin Receptor Ligands in AcromegalySemantic proximity Read ↗

Treatment of acromegaly in the era of personalized and predictive medicine.Semantic proximity Read ↗

Efficacy and Safety of Pasireotide Treatment in Acromegaly: A Systematic Review and Single Arm Meta-AnalysisSemantic proximity Read ↗

Common polymorphisms in SOCS3 are not associated with body weight, insulin sensitivity or lipid profile in normal female twins.Semantic proximity Read ↗

Growth hormone receptor variants and response to pegvisomant in monotherapy or in combination with somatostatin analogs in acromegalic patients: a multicenter study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.